5-Year Global Study on MAST™ Minimally Invasive Fusion Procedures to Treat Degenerative Lumbar Spine (MASTERS-D2)

NCT ID: NCT02617563

Last Updated: 2026-01-21

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 361 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2015-12-31
• Study Completion Date: 2024-11-14

Brief Summary

The purpose of this study is

• to evaluate the effectiveness of MAST techniques for anterior/lateral and posterior approaches in Degenerative Disc Disease (DDD) patients with spondylolisthesis (≥ grade I).
• To assess how single or double level MAST(Minimal Access Spinal Technologies) fusion procedures PLIF (Posterior Lumbar Interbody Fusion), TLIF (Transforaminal Lumbar Interbody Fusion), DLIF (Direct Lateral Interbody Fusion), OLIF (Oblique Lumbar Interbody Fusion), ALIF (Anterior Lumbar Interbody Fusion), or MIDLF (Midline Lumbar Interbody Fusion) are used in surgical practice and to describe long-term safety and effectiveness in a broad patient population of patients with degenerative lumbar disc disease .

Detailed Description

In this Prospective, Global (multi center), Post Market Release (PMR) Study, Patients will be submitted to a single or double level instrumented fusion procedure using a PLIF, TLIF, ALIF, OLIF, DLIF or MIDLF technique via a minimally invasive procedure and will receive the same medical treatment as if they would not participate in this study.

• The study will be monitored with visits conducted at the start, during and at the closure of the clinical study.
• MedDRA coding will be used to classify the Adverse Event.
• The study will be conducted according to Medtronic SOPs
• Sample size calculation: Assuming that the standard deviation for ODI improvement at 3 months is 20 for both groups (anterolateral and posterior) and there is no difference in the mean ODI improvement at 3 months, with 80% power and 5% alpha level, the sample size for the primary endpoint (DDD patients operated for spondylolisthesis) is as follows in order to claim equivalence between two groups with equivalent margin (-10, 10):
• Estimated sample size per group (anterolateral procedures versus posterior procedures): 70
• Estimated total sample size for spondylolisthesis patients: 140
• From the MASTERS-D study it is know that approximately 50% of the patients with degenerative disc disease have spondylolisthesis ≥ grade I. Hence the required total sample size is 140/0.5 = 280. The study is anticipated to enroll 350 patients.
• In addition to a final statistical analysis, 3 months and annual interim analyses are anticipated.
• The study hypothesis for the primary objective is to verify whether patients operated for spondylolisthesis (≥ grade I) have equivalent mean improvement of ODI at 3 months regardless of the minimally invasive surgical procedure (anterolateral or posterior) used.
• The null-hypothesis: Ho: Δ ODI_Anterolateral ≠ Δ ODI_posterior
• will be tested against the alternative hypothesis: HA: Δ ODI_Anterolateral = Δ ODI_posterior Where Δ ODI_Anterolateral is the average improvement in ODI score (baseline - 3 months) in spondylolisthesis subjects treated with the anterolateral approach and Δ ODI_posterior is the average improvement in ODI score (baseline - 3 months) in spondylolisthesis subjects treated with the posterior approach.

Conditions

Intervertebral Disc Degeneration

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Minimally invasive lumbar fusion

A single or double level instrumented fusion using minimally invasive PLIF, TLIF, MIDLF, DLIF, OLIF, ALIF procedures for the treatment of the degenerative lumbar spine.

Minimally invasive lumbar fusion

Intervention Type: DEVICE

Patients will receive a single or double level instrumented fusion using a minimally invasive/MAST™ PLIF, TLIF, DLIF, OLIF, ALIF or MIDLF surgical procedure with a posterior fixation. For the use of a posterior fixation system, the CD Horizon™ Spinal System, is mandatory in this study and will be either mini-open and/or percutaneous.

Interventions

Minimally invasive lumbar fusion

Patients will receive a single or double level instrumented fusion using a minimally invasive/MAST™ PLIF, TLIF, DLIF, OLIF, ALIF or MIDLF surgical procedure with a posterior fixation. For the use of a posterior fixation system, the CD Horizon™ Spinal System, is mandatory in this study and will be either mini-open and/or percutaneous.

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Patient is ≥ 18 years of age (or minimum age as required by local regulations)
• Patient has degenerative disc disease and an indication for a single or double level instrumented lumbar fusion for the treatment
• Patient agrees to participate in the study and is able to sign the Data Release Form/Informed Consent
• The procedure planned for the patient complies with the labeling of the Devices that may be used in the surgical procedure as described in the section Medical Devices of the Clinical Investigation Plan
• Patient is planned to be submitted to a minimally invasive fusion procedure using a posterior (PLIF, TLIF, MIDLF) or anterolateral (OLIF, ALIF, DLIF ) technique*

*For a double level instrumented fusion, the same procedure must be used for both levels.

• The patient is willing and is able to perform study procedures and required follow-up visits.

Exclusion Criteria

• Patient that has already undergone a lumbar fusion surgery
• Patient that has already undergone open lumbar surgery other than standard decompression surgery
• Indications for the procedure other than degenerative spine disease like: Osteoporotic vertebral fractures, Spine trauma fractures or Spine tumor
• Illiterate or vulnerable patients (e.g. minors, participants incapable of judgment or participants under tutelage)
• Concurrent participation in another clinical study that may confound study results.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Medtronic Spinal and Biologics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Hospital Italiano de Buenos Aires

Buenos Aires, , Argentina

Kepler Universitatsklinikum

Linz, , Austria

AZ Delta

Roeselare, , Belgium

Hospital Universitario Cajuru

Curitiba, , Brazil

The First Affiliated Hospital of Dalian Medical University

Dalian, Liaoning, China

West China Hospital Sichuan University

Chengdu, Sichuan, China

Shangai Tenth People's Hospital

Shanghai, , China

Nový Hradec Králové

Hradec Králové, , Czechia

Glostrup Hospital

Glostrup Municipality, , Denmark

Hôpital Civil de Strasbourg (NHC)

Eckbolsheim, , France

CHRU de Lille, Hôpital Roger Salengro

Lille, , France

Service de Neurochirurgie la Timone

Marseille, , France

Klinikum Magdeburg

Magdeburg, , Germany

A.O. Fatebenefratelli e Oftalmico

Milan, , Italy

Hospital Naval General de Alta Especialidad

Mexico City, , Mexico

Hospital Escala Braga

Braga, , Portugal

Centro Hospitalar de Sao Joao

Porto, , Portugal

Nizhny Novgorod Research Institute of Traumatology and Orthopedics of Public Health Ministry

Nizhny Novgorod, , Russia

Scientific Research Institute of Traumatology and Orthopedics

Novosibirsk, , Russia

A-klinik

Bratislava, , Slovakia

Department of Orthopedics, Korea University Ansan Hospital

Ansan, , South Korea

National Health Insurance Corporation Ilsan Hospital

Gyeonggi-do, , South Korea

Department of Neurological Surgery, Chung-Ang University Hospital

Seoul, , South Korea

Hospital Universitario Marques de Valdecilla

Santander, , Spain

Hospital L'Horta Manises

Valencia, , Spain

Hull Royal Infirmary

Hull, , United Kingdom

East Suffolk and North Essex NHS Foundation Trust (was formerly Ipswich Hospital NHS)

Ipswich, , United Kingdom

Countries

Argentina; Austria; Belgium; Brazil; China; Czechia; Denmark; France; Germany; Italy; Mexico; Portugal; Russia; Slovakia; South Korea; Spain; United Kingdom

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

P15-01

Identifier Type: -

Identifier Source: org_study_id